The second National CARE™ Congress was a great success!
Thank you to all those who attended.
The second National CARE™ Congress: Update on Biosimilars and Access to Innovation was held at the Shangri-La Hotel in Toronto on April 6th, 2018. The meeting addressed questions and considerations regarding biosimilars in Canada and how they build towards a larger discussion on access to innovative medicine. The meeting included discussion and provided a platform for medical specialists and key stakeholders across multiple fields to meet, collaborate, and discuss concepts that have a practical impact on the Canadian healthcare landscape.
Friday, April 6th, 2018
Registration & Lunch 11:15 – 12:00 pm
Meeting Sessions 12:00 – 5:00 pm
188 University Ave, Toronto, ON
Queens Park South Meeting Room
John Marshall, MD – McMaster University
John Kuruvilla, MD – Princess Margaret Cancer Centre
The CARE™ Congress aims to allow assembled CARE™ faculty and panelists to consider the use of biosimilars and align on the importance of access to innovation.
The CARE™ Faculty is pleased to welcome a robust speaker line-up, with representation from Canadian researchers, clinicians, government, public and private funding agencies, health economists, hospital pharmacists, nurses, advocacy groups, ethicists and legal experts.
Section 1: Update on Biosimilars
The first section of the 2018 CARE™ Congress on Biosimilars and Access to Innovation focused on biosimilars. After an opening from the Congress Chairs, Dr. John Marshall and Scott Edwards presented on CARE™ education initiatives in biosimilars and gaps in knowledge that still exist in Canada. This was followed by a multidisciplinary discussion.
Section 2: Access to Innovation
In the second section of the 2018 CARE™ Congress, participants were involved in the following four plenary sessions on access to innovation: Translational Science & Innovation to Access, Drug Approval and Public Pricing, Private Payer Perspectives, and Patient Perspectives. Multi-stakeholder discussions took place after the first three presentations.
Plenary Session 1:
Plenary Session 2:
Plenary Session 3:
Plenary Session 4:
CARE™ receives funding from multi-industry sponsors at arm’s length. Content reflects the opinions, output and analyses of experts, investigators, educators and clinicians (“CARE™ Faculty”), whose activities, while independent, are commercially supported by the noted sponsor(s). Program content is developed independently of sponsor(s). This content is intended for educational value only; to make scientific information and opinions available to health professionals, to stimulate thought, and further investigation.